REG - Arecor Therapeutics - Grant of AESOP Options and PDMR Dealing
17/11/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221117:nRSQ6906Ga&default-theme=true
RNS Number : 6906G Arecor Therapeutics PLC 17 November 2022
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
Grant of AESOP Options, PDMR Dealing
Cambridge, UK, 17 November 2022: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier
lives, announces that on 16 November 2022, it granted a total of 323,500
options under the Company's All Employee Share Ownership Plan ("AESOP
Options") over new ordinary shares of 0.1 pence each in the Company ("Ordinary
Shares").
The AESOP Options vest after 36 months and are exercisable at £2.45 per share
being the closing market price of an Ordinary Share on the day preceding the
date of grant. The AESOP Options are subject to continuous employment, vest in
accordance with the vesting term notified to the option holder and are
exercisable until the tenth anniversary of the date of grant, after which date
the option will lapse.
The following 159,000 AESOP Options were granted to persons discharging
managerial responsibilities ("PDMR"):
PDMR Position/status Number of AESOP options granted on 16 November 2022 Total number of AESOP options held
Shafiq Choudhary Managing Director, Tetris Pharma 40,000 40,000
David Gerring VP Development 40,000 70,000
Sarah Howell Chief Executive Officer 33,000 133,000
Jan Jezek Chief Scientific Officer 13,000 53,000
Fiona Lawrence VP Clinical Development and Reg. Affairs 10,000 40,000
Susan Lowther Chief Financial Officer 23,000 93,000
The notifications below, made in accordance with the requirements of the
Market Abuse Regulation, provide further detail.
For further information, please contact:
Arecor Therapeutics plc www.arecor.com (http://www.arecor.com/)
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com (mailto:sarah.howell@arecor.com)
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com (mailto:info@arecor.com)
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)
Panmure Gordon (UK) Limited Tel: +44 (0) 20 7886 2500
(NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Gray Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat ™
platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
(http://www.arecor.com/)
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Shafiq Choudhary
2. Reason for the notification
a) Position/status: Managing Director, Tetris Pharma
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of options over ordinary shares
c) Price(s) and volume(s): Exercise Price(s) Volume(s)
£2.45 40,000
d) Aggregated information:
· Aggregated volume: 40,000
· Price: N/A
e) Date of the transaction: 16 November 2022
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
40,000
N/A
e)
Date of the transaction:
16 November 2022
f)
Place of the transaction:
Outside of a trading venue
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: David Gerring
2. Reason for the notification
a) Position/status: VP Development
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of options over ordinary shares
c) Price(s) and volume(s): Exercise Price(s) Volume(s)
£2.45 40,000
d) Aggregated information:
· Aggregated volume: 40,000
· Price: N/A
e) Date of the transaction: 16 November 2022
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
40,000
N/A
e)
Date of the transaction:
16 November 2022
f)
Place of the transaction:
Outside of a trading venue
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Sarah Howell
2. Reason for the notification
a) Position/status: Chief Executive Officer
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of options over ordinary shares
c) Price(s) and volume(s): Exercise Price(s) Volume(s)
£2.45 33,000
d) Aggregated information:
· Aggregated volume: 33,000
· Price: N/A
e) Date of the transaction: 16 November 2022
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
33,000
N/A
e)
Date of the transaction:
16 November 2022
f)
Place of the transaction:
Outside of a trading venue
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Jan Jezek
2. Reason for the notification
a) Position/status: Chief Scientific Officer
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of options over ordinary shares
c) Price(s) and volume(s): Exercise Price(s) Volume(s)
£2.45 13,000
d) Aggregated information:
· Aggregated volume: 13,000
· Price: N/A
e) Date of the transaction: 16 November 2022
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
13,000
N/A
e)
Date of the transaction:
16 November 2022
f)
Place of the transaction:
Outside of a trading venue
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Fiona Lawrence
2. Reason for the notification
a) Position/status: VP Clinical Development and Reg. Affairs
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of options over ordinary shares
c) Price(s) and volume(s): Exercise Price(s) Volume(s)
£2.45 10,000
d) Aggregated information:
· Aggregated volume: 10,000
· Price: N/A
e) Date of the transaction: 16 November 2022
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
10,000
N/A
e)
Date of the transaction:
16 November 2022
f)
Place of the transaction:
Outside of a trading venue
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Susan Lowther
2. Reason for the notification
a) Position/status: Chief Financial Officer
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of options over ordinary shares
c) Price(s) and volume(s): Exercise Price(s) Volume(s)
£2.45 23,000
d) Aggregated information:
· Aggregated volume: 23,000
· Price: N/A
e) Date of the transaction: 16 November 2022
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
23,000
N/A
e)
Date of the transaction:
16 November 2022
f)
Place of the transaction:
Outside of a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCEANFKFDKAFFARecent news on Arecor Therapeutics
See all newsREG - Arecor Therapeutics - BOARD CHANGE
AnnouncementREG - Arecor Therapeutics - Arecor and TRx Biosciences research collaboration
AnnouncementRCS - Arecor Therapeutics - Arecor and TRx Biosciences research collaboration
AnnouncementREG - Arecor Therapeutics - Arecor announces launch of Ogluo® in Netherlands
AnnouncementREG - Arecor Therapeutics - Year End Trading Update
Announcement